Garsorasib Shows 45.5% Response Rate in KRAS G12C-Mutated Pancreatic Cancer Patients
核心洞察
Garsorasib, an oral KRAS G12C (搜索) inhibitor, achieved a 45.5% objective response rate in 22 evaluable patients with advanced pancreatic cancer (搜索) carrying the KRAS G12C mutation.
The median progression-free survival reached 7.6 months with a median duration of response of 6.4 months in pooled data from two international phase 1/2 trials.
Treatment-related adverse events occurred in 75% of patients, with 25% experiencing grade 3 or higher side effects, but no patients discontinued treatment due to adverse events.
Garsorasib (D-1553), a highly selective oral KRAS G12C (搜索) inhibitor, demonstrated encouraging antitumor activity in patients with advanced pancreatic cancer (搜索) carrying the KRAS G12C mutation, according to pooled data from two international phase 1/2 clinical trials. The results offer fresh hope for patients with this rare form of pancreatic cancer, which remains among the most challenging malignancies to treat.
Clinical Trial Results
As of April 30, 2024, 24 patients with KRAS G12C (搜索)-mutated pancreatic cancer (搜索) were enrolled across two multicenter, open-label trials (NCT04585035 and NCT05383898) with similar eligibility criteria. Participants received garsorasib 600 mg twice daily treatment, with a median follow-up of 8.9 months (range 1.1-22.9).
Among 22 evaluable patients, the confirmed objective response rate reached 45.5% (95% CI, 24.4 to 67.8), meaning nearly half saw their tumors shrink. The median duration of response was 6.4 months (95% CI, 4.2 to 16.4), while median progression-free survival was 7.6 months (95% CI, 3.3 to 8.5).
The 6-month overall survival rate was 79.2% (95% CI, 57.0 to 90.8), representing a notable outcome in a cancer where survival is often measured in months.
Safety Profile
Treatment-related adverse events occurred in 18 patients (75.0%), with most being mild to moderate in severity. Six patients (25.0%) experienced grade 3 or higher side effects, but notably, no treatment-related adverse events led to treatment discontinuation. The safety profile was consistent with previous reports of garsorasib in other cancer types.
Targeting KRAS G12C Mutations
KRAS G12C (搜索) accounts for only a small share of pancreatic cancer (搜索) cases, but identifying this mutation allows patients to receive precision therapies designed to shut down a key cancer growth pathway. Pancreatic cancer with KRAS mutations is notoriously resistant to treatment, making targeted approaches particularly valuable for this patient population.
Garsorasib has already demonstrated clinical efficacy in non-small cell lung cancer and colorectal cancer (搜索), and these results extend its potential therapeutic application to pancreatic cancer (搜索) patients with the specific KRAS G12C (搜索) mutation.
Clinical Significance
Pancreatic cancer (搜索) remains one of the leading causes of cancer deaths worldwide, with few targeted therapies proving effective. While these trials are still in early phases and involve a small patient population, the results represent a meaningful step forward for precision medicine in pancreatic cancer treatment.
The investigators concluded that the findings support continued development of garsorasib as a treatment option for KRAS G12C (搜索)-mutated pancreatic cancer (搜索), with larger studies now needed to confirm the benefit and understand how long responses can be sustained.